On Nov 09, major Wall Street analysts update their ratings for $Arcellx (ACLX.US)$, with price targets ranging from $105 to $122.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and adjusts the target price from $106 to $111.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $120.
Needham analyst Gil Blum maintains with a buy rating, and adjusts the target price from $96 to $105.
Stifel analyst Benjamin Burnett maintains with a buy rating, and maintains the target price at $122.
William Blair analyst Sami Corwin maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcellx (ACLX.US)$'s main analysts recently are as follows:
The assessment of Arcellx's anito-cel success probabilities has been revised upward after reviewing initial data from the iMMagine-1 Phase 2 trial in patients with relapsed/refractory multiple myeloma. Analysts perceive a significant opportunity for market share capture by anito-cel, initially among patients treated in later stages, and potentially extending to those in earlier stages if the current clinical outcomes are sustained.
The analyst noted that recent abstracts including initial Phase 2 data and additional Phase 1 follow-up data reinforce the competitive positioning and regulatory progress of pivotal-stage anito-cel in the treatment of multiple myeloma. Despite a recent decline in share price, which is viewed as a 'sell the news' reaction following a significant rise due to abstract anticipation, the analyst's perspective is that anito-cel is poised to secure a more formidable peak market share with increased probability of success.
The firm expressed a growing positive stance regarding the updated clinical data. The release of ASH abstracts online, which included initial data from the IMMagine-1 study, contributed to this view.
Here are the latest investment ratings and price targets for $Arcellx (ACLX.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月9日，多家華爾街大行更新了$Arcellx (ACLX.US)$的評級，目標價介於105美元至122美元。
摩根士丹利分析師Judah Frommer維持買入評級，並將目標價從106美元上調至111美元。
Evercore分析師Cory Kasimov維持買入評級，維持目標價120美元。
Needham分析師Gil Blum維持買入評級，並將目標價從96美元上調至105美元。
斯迪富分析師Benjamin Burnett維持買入評級，維持目標價122美元。
威廉博萊分析師Sami Corwin維持買入評級。
此外，綜合報道，$Arcellx (ACLX.US)$近期主要分析師觀點如下：
Arcellx的anito-cel成功概率評估在審閱了iMMagine-1第2期試驗中初步數據後被上調。分析師認爲anito-cel在市場份額佔領方面存在重大機會，最初主要針對晚期接受治療的患者，並且如果目前的臨床結果持續下去，有可能延伸到早期接受治療的患者。
分析師指出，最近的摘要，包括初步第2期數據和額外的第1期後續數據，強化了anito-cel在治療多發性骨髓瘤中的競爭定位和監管進展。儘管股價最近有所下跌，這被視爲對摘要預期產生顯著上漲的'賣出資訊'反應，分析師認爲anito-cel有望在更高的市場份額上取得更爲可觀的峯值，成功的可能性也有所增加。
該公司對更新的臨床數據表示日益樂觀的態度。ASH摘要在線發佈，其中包括了iMMagine-1研究的初步數據，這一觀點得到了支持。
以下爲今日7位分析師對$Arcellx (ACLX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
